Lung Cancer Biomarkers
& Targeted Therapy
If you have a lung cancer biomarker report, call us. We can help you organize the findings and questions for an individualized review.
In NSCLC, the molecular profile can change first-line treatment, clinical-trial options and what to test after progression.
Call 1.800.923.7878The introductory call with our Patient Care Team is free. Medical recommendations require a physician consultation.
Talk With Our Lung Cancer Patient Care Team
Tell us what you are facing. Our Patient Care Team will follow up personally, explain the consultation process and help you understand the next step. The introductory call is free.
A biomarker report is a decision tool—not a complete treatment plan
Biomarker testing looks for features of the tumor that can help select treatment. In non-small cell lung cancer, testing may identify a molecular alteration with a matched targeted therapy, help guide immunotherapy, support a clinical-trial search or explain why a particular option is unlikely to help.
Molecular alterations and PD-L1 answer different questions
Broad molecular testing can evaluate multiple genes and alteration types in one panel. PD-L1 is an immune marker reported separately. The exact testing needed depends on the NSCLC subtype, stage, sample, prior treatment and current decision.
- Complete pathology subtype
- Genes and alteration types on the panel
- PD-L1 percentage and assay
- Sample source and collection date
- Tissue adequacy and tumor content
- Whether a blood-based assay was also used
- Actionable, uncertain and negative findings
- Whether the result changes treatment now
A blood result can add information but does not replace every tissue question
Tissue confirms the cancer and can provide histology plus molecular information. A liquid biopsy measures tumor-derived material in blood and can be useful when tissue is limited or after progression. A positive result can be informative; a negative blood test may need follow-up because not every tumor sheds enough material.
A matched treatment still requires the right setting and safety review
Targeted therapies are designed for particular molecular changes. They can produce substantial responses in appropriate patients, but they can also cause side effects and resistance. The oncology team must consider the exact variant, stage, prior therapy, brain activity, medicine interactions and organ function.
Resistance testing can clarify the next question
When a targeted therapy stops controlling disease, progression may occur through a new molecular mechanism or through changes not captured by the original test. Repeat tissue or blood testing, imaging pattern and clinical-trial review may help guide the next choice.
Continue with the part of the diagnosis that matters now
Talk with our Patient Care Team for free
If you are facing biomarker-defined lung cancer, call us. We can help you organize the diagnosis, reports and questions that deserve a closer review. The introductory call is free and does not obligate you to schedule a consultation.
Frequently asked questions
Is biomarker testing the same as genetic testing?
Tumor biomarker testing looks for changes in the cancer. Germline genetic testing looks for inherited changes. They can overlap but answer different questions.
What if my biomarker test is negative?
Confirm that the correct alterations were tested with an adequate method and sample. A negative blood test may not exclude a tumor alteration.
Does a targetable mutation guarantee a response?
No. It may make a targeted treatment appropriate, but response and duration vary, and the full clinical context still matters.
Sources and important context
- Non-Small Cell Lung Cancer Treatment (PDQ®)
- Small Cell Lung Cancer Treatment (PDQ®)
- Biomarker Testing for Cancer Treatment
- Finding Cancer Care and Seeking a Second Opinion
- Cancer Therapy Interactions With Foods and Dietary Supplements
Medical information disclaimer: This page is for education and does not diagnose lung cancer or recommend a treatment plan. Decisions require review of the exact pathology, stage, biomarkers, prior treatment, medicines, symptoms and overall health. Do not start, stop or replace cancer treatment based on website content.